Please login to the form below

Not currently logged in
Email:
Password:

XenoPort appoints chief medical officer

Richard Kim led Tysabri programme at Biogen Idec

XenoPort has appointed Dr Richard Kim as chief medical officer and senior VP, clinical development and medical affairs.

Dr Kim has been with the US biopharma company since July 2013, when he joined as VP of medical affair, supporting the marketing of Horizant (gabapentin enacarbil) in restless legs syndrome and postherpetic neuralgia.

He joined XenoPort from Biogen Idec where he was joint programme team leader for the hugely successful multiple sclerosis (MS) treatment Tysabri (natalizumab) helping with drug's launches in markets that included the US.

Prior to joining Biogen Idec Dr Kim was with Merck Serono, serving as medical director for the phase III programme of cladribine, which failed to impress in MS.

XenoPort will look to Dr Kim's experience as it prepares to advance its drug candidate XP23829, which is being studied as a treatment for psoriasis and/or relapsing forms of MS, into phase II development.

6th February 2014

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....